Remus Pharmaceuticals Share Price
Sector:
You have to be logged in to add this to Watchlist.
Login or Register
2004.00 -13.00 (-0.64%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2000.00
Today’s High
2025.00
52 Week Low
1412.50
52 Week High
2834.75
Key Metrics
- Market Cap (In Cr) 1180.76
- Beta -
- Div. Yield (%) 0.1
- P/B 13.59
- TTM P/E 51.64
- Sector P/E 22.83
- D/E 0
Remus Pharmaceuticals Analysis
Price Analysis
-
1 Week-2.67%
-
3 Months-9.86%
-
6 Month-24.09%
-
YTD-19.76%
-
1 Year35.89%
Remus Pharmaceuticals News
Remus Pharmaceuticals SME IPO: Issue subscribed 6.41x on Day 2, check GMP and other key details
3 min read . 18 May 2023
Remus Pharma IPO: Issue date, GMP, subscription status, other details to know about the issue
1 min read . 17 May 2023Remus Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 212.5
- Selling/ General/ Admin Expenses Total
- 20.35
- Depreciation/ Amortization
- 0.9
- Other Operating Expenses Total
- 0.02
- Total Operating Expense
- 185.59
- Operating Income
- 26.91
- Net Income Before Taxes
- 31.83
- Net Income
- 21.54
- Diluted Normalized EPS
- 35.82
- Period
- 2024
- Total Assets
- 257.27
- Total Liabilities
- 170.42
- Total Equity
- 86.86
- Tangible Book Valueper Share Common Eq
- 131.52
- Period
- 2024
- Cashfrom Operating Activities
- 3.6
- Cashfrom Investing Activities
- -8.94
- Cashfrom Financing Activities
- 24.37
- Net Changein Cash
- 19.03
- Period
- 2023
- Total Revenue
- 45.03
- Selling/ General/ Admin Expenses Total
- 13.02
- Depreciation/ Amortization
- 0.48
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 34.96
- Operating Income
- 10.07
- Net Income Before Taxes
- 11.41
- Net Income
- 8.5
- Diluted Normalized EPS
- 20.84
- Period
- 2023
- Total Assets
- 34.66
- Total Liabilities
- 15.53
- Total Equity
- 19.14
- Tangible Book Valueper Share Common Eq
- 43.98
- Period
- 2023
- Cashfrom Operating Activities
- 5.31
- Cashfrom Investing Activities
- -15.19
- Cashfrom Financing Activities
- 11.77
- Net Changein Cash
- 1.89
- Period
- 2022
- Total Revenue
- 24.72
- Selling/ General/ Admin Expenses Total
- 8.37
- Depreciation/ Amortization
- 0.15
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 20.8
- Operating Income
- 3.92
- Net Income Before Taxes
- 4.55
- Net Income
- 3.39
- Diluted Normalized EPS
- 5.75
- Period
- 2022
- Total Assets
- 15.91
- Total Liabilities
- 9.48
- Total Equity
- 6.43
- Tangible Book Valueper Share Common Eq
- 10.92
- Period
- 2022
- Cashfrom Operating Activities
- 5.04
- Cashfrom Investing Activities
- -4.55
- Cashfrom Financing Activities
- -0.17
- Net Changein Cash
- 0.32
- Period
- 2021
- Total Revenue
- 18.42
- Selling/ General/ Admin Expenses Total
- 6.15
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 0.01
- Total Operating Expense
- 17.83
- Operating Income
- 0.59
- Net Income Before Taxes
- 1.36
- Net Income
- 1.03
- Diluted Normalized EPS
- 1.74
- Period
- 2021
- Total Assets
- 11.05
- Total Liabilities
- 8
- Total Equity
- 3.05
- Tangible Book Valueper Share Common Eq
- 5.17
- Period
- 2021
- Cashfrom Operating Activities
- 2.84
- Cashfrom Investing Activities
- -3.09
- Cashfrom Financing Activities
- -0.12
- Net Changein Cash
- -0.37
- Period
- 2020
- Total Revenue
- 11.92
- Selling/ General/ Admin Expenses Total
- 4.48
- Depreciation/ Amortization
- 0.11
- Other Operating Expenses Total
- 0.01
- Total Operating Expense
- 11.63
- Operating Income
- 0.29
- Net Income Before Taxes
- 1.09
- Net Income
- 0.81
- Diluted Normalized EPS
- 1.38
- Period
- 2020
- Total Assets
- 5.3
- Total Liabilities
- 3.28
- Total Equity
- 2.02
- Tangible Book Valueper Share Common Eq
- 3.43
- Period
- 2020
- Cashfrom Operating Activities
- 1.3
- Cashfrom Investing Activities
- -0.56
- Cashfrom Financing Activities
- 0.06
- Net Changein Cash
- 0.81
- Period
- 2024-09-30
- Total Revenue
- 272.68
- Selling/ General/ Admin Expenses Total
- 5.89
- Depreciation/ Amortization
- 0.38
- Other Operating Expenses Total
- 14.44
- Total Operating Expense
- 252.56
- Operating Income
- 20.13
- Net Income Before Taxes
- 22.27
- Net Income
- 14.01
- Diluted Normalized EPS
- 23.78
- Period
- 2024-09-30
- Total Assets
- 221.39
- Total Liabilities
- 120.9
- Total Equity
- 100.49
- Tangible Book Valueper Share Common Eq
- 154.67
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 10.21
- Cashfrom Investing Activities
- 0.97
- Cashfrom Financing Activities
- 7.95
- Net Changein Cash
- 19.13
- Period
- 2024-03-31
- Total Revenue
- 183.46
- Selling/ General/ Admin Expenses Total
- 4.13
- Depreciation/ Amortization
- 0.48
- Other Operating Expenses Total
- 10.06
- Total Operating Expense
- 165.39
- Operating Income
- 18.07
- Net Income Before Taxes
- 21.42
- Net Income
- 15.89
- Diluted Normalized EPS
- 26.96
- Period
- 2024-03-31
- Total Assets
- 257.27
- Total Liabilities
- 170.42
- Total Equity
- 86.86
- Tangible Book Valueper Share Common Eq
- 131.52
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 3.6
- Cashfrom Investing Activities
- -8.94
- Cashfrom Financing Activities
- 24.37
- Net Changein Cash
- 19.03
- Period
- 2023-09-30
- Total Revenue
- 29.04
- Selling/ General/ Admin Expenses Total
- 3.29
- Depreciation/ Amortization
- 0.42
- Other Operating Expenses Total
- 2.88
- Total Operating Expense
- 20.19
- Operating Income
- 8.85
- Net Income Before Taxes
- 10.41
- Net Income
- 5.65
- Diluted Normalized EPS
- 10.38
- Period
- 2023-09-30
- Total Assets
- 85.54
- Total Liabilities
- 14.06
- Total Equity
- 71.48
- Tangible Book Valueper Share Common Eq
- 121.25
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 5.28
- Cashfrom Investing Activities
- -8.93
- Cashfrom Financing Activities
- -16.57
- Net Changein Cash
- -20.21
- Period
- 2023-03-31
- Total Revenue
- 12.64
- Selling/ General/ Admin Expenses Total
- 3.9
- Depreciation/ Amortization
- 0.14
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 10.17
- Operating Income
- 2.46
- Net Income Before Taxes
- 2.72
- Net Income
- 2.06
- Diluted Normalized EPS
- 5.05
- Period
- 2023-03-31
- Total Assets
- 34.66
- Total Liabilities
- 15.53
- Total Equity
- 19.14
- Tangible Book Valueper Share Common Eq
- 43.98
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 5.31
- Cashfrom Investing Activities
- -15.19
- Cashfrom Financing Activities
- 11.77
- Net Changein Cash
- 1.89
- Period
- 2022-12-31
- Total Revenue
- 32.39
- Selling/ General/ Admin Expenses Total
- 9.12
- Depreciation/ Amortization
- 0.33
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 24.78
- Operating Income
- 7.61
- Net Income Before Taxes
- 8.69
- Net Income
- 6.44
- Diluted Normalized EPS
- 10.95
- Period
- 2022-12-31
- Total Assets
- 33.53
- Total Liabilities
- 16.41
- Total Equity
- 17.12
- Tangible Book Valueper Share Common Eq
- 29.03
- Period
- 2022-12-31
- Cashfrom Operating Activities
- 5.32
- Cashfrom Investing Activities
- -14.51
- Cashfrom Financing Activities
- 13.4
- Net Changein Cash
- 4.21
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Remus Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Irm Energy
- 299.55
- 1.2
- 0.4
- 635
- 235.9
- 1229.94
- Sathlokhar Synergys E&c Global
- 507.05
- -12.2
- -2.35
- 695.45
- 222.95
- 1223.92
- Remus Pharmaceuticals
- 2004
- -13
- -0.64
- 2834.75
- 1412.5
- 1180.76
- Ecos India Mobility & Hospitalit
- 196.05
- -5.6
- -2.78
- 592.95
- 166
- 1176.3
- Borosil Scientific
- 132.75
- -0.65
- -0.49
- 229.8
- 109.8
- 1180.59
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Irm Energy
- 12.24
- 1.35
- -
- -
- Sathlokhar Synergys E&c Global
- 46.79
- 30.2
- -
- -
- Remus Pharmaceuticals
- 55.94
- 13.59
- -
- -
- Ecos India Mobility & Hospitalit
- 18.87
- 6.65
- -
- -
- Borosil Scientific
- 49.74
- 3.13
- -
- -
Remus Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 09-Nov-24
- Quarterly Results & Interim Dividend
- 16-May-24
- Audited Results
- 23-Apr-24
- Bonus issue & Interim Dividend
- 22-Apr-24
- Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 20-Sept-24
- 14-Aug-24
- AGM
- 22-Sept-23
- 31-Aug-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 09-Nov-24
- 20-Nov-24
- 19-Nov-24
- 1
- 23-Apr-24
- 02-May-24
- 02-May-24
- 4
- 19-Oct-23
- 28-Oct-23
- 27-Oct-23
- 2
- Announced on
- Record Date
- Ex-Bonus
- Description
- 23-Apr-24
- 06-Jun-24
- 06-Jun-24
- Bonus issue in the ratio of 3:1 of Rs. 10/-.
